Therapeutic ethics and communities at risk in the presence of potential mutation to resistant strains to HIV antiviral medications

AIDS

Volumn 12, Issue 16, 1998, Pages 2089-2093

  Friedman, Samuel R ^a   Wainberg, Mark A ^b   Drucker, Ernest ^c,d  

^a NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d Lindesmith Center   (United States)

Author keywords

AIDS; Combination therapy; Communities; Ethics; HIV; Policy; Resistant strains

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MEDICAL ETHICS; PRIORITY JOURNAL; REVIEW; VIRUS LOAD; VIRUS TRANSMISSION;

HEALTH CARE AND PUBLIC HEALTH;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; ETHICS, MEDICAL; HIV; HIV INFECTIONS; HUMANS; MUTATION; PATIENT COMPLIANCE; RISK FACTORS; RNA, VIRAL; SEMEN; VIRAL LOAD;

EID: 0032511922     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199816000-00003     Document Type: Review

References (37)

1. Senak M: Predicting antiviral compliance: physicians' responsibilities vs patients' rights. J Int Assoc Physicians AIDS Care 1997, 3:45-48.
2. Sontag D, Richardson J: Doctors withhold HIV pill regimen from some. New York Times, 2 March 1997:A1.
3. Bayer R: Ethical challenges posed by new advances in the antiretroviral treatment of HIV disease. In The Implications of Antiretroviral Treatments: Informal Consultation. Edited by van Praag E, Fernyak S, Katz AM. Geneva: World Health Organization; 1997:95-101.
4. Bayer R, Stryker J: Ethical challenges posed by clinical progress in AIDS. Am J Public Health 1997, 87:1599-1602.
5. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW: The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993, 328:521-526.
6. Chaulk C, Moore-Rice K, Rizzo R, Chaisson R: Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995, 274:945-951.
7. Longuet P, Pierre J, Lacassin F, et al.: A limited multidrug-resistant Mycobacterium tuberculosis outbreak: screening of contact hospitalized patients (pts). 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1995 [abstract].
8. Bifani P, Plikaytis B, Kapur V, et al.: Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. JAMA 1996, 275:452-457.
9. Des Jarlais DC, Hagan H, Friedman SR: Epidemiology and emerging public health perspectives. In Substance Abuse. A Comprehensive Textbook. Third Edn. Edited by Lowinson JH, Ruiz P, Millman RB, Langrod JG, Baltimore: Williams & Wilkins; 1997:591-597.
10. Perlman DC, Perkins MP, Solomon N, Kochems L, Des Jarlais DC, Paone D: Tuberculosis screening at a syringe exchange program. Am J Public Health 1997, 87:862-863.
11. Perlman D, Salomon N, Garcia de Soria V, et al.: Tuberculosis directly observed preventive therapy for active drug users in two settings. College on the Problems of Drug Dependence Annual Meeting. Nashville, June 1997 [abstract].
12. Altman D: The primacy of politics: organizing around AIDS. AIDS 1991, 5 (suppl 2):S231-S238.
13. Coates TJ, Aggleton P, Gutzwiller F, et al.: HIV prevention in developed countries. Lancet 1996, 348:1143-1148.
14. Friedman SR, de Jong W, Wodak A: Community development as a response to HIV among drug injectors. AIDS 1993, 7 (suppl 1):S263-S269.
15. Friedman SR, Des Jarlais DC, Sotheran JL, Garber J, Cohen H, Smith D: AIDS and self-organization among intravenous drug users. Int J Addict 1987, 22:201-219.
16. Neaigus A, Friedman SR, Curtis R, et al.: The relevance of drug injectors' social and risk networks for understanding and preventing HIV infection. Soc Sci Med 1994, 38:67-78.
17. Des Jarlais DC, Friedmann P, Hagan H, Friedman SR: The protective effect of AIDS-related behavioral change among injection drug users: a cross-national study. Am J Public Health 1996, 86:1780-1785.
18. Curtis R, Friedman SR, Neaigus A, Jose B, Goldstein M, Des Jarlais DC: Implications of directly observed therapy in tuberculosis control measures among IDUs. Public Health Rep 1994, 109:319-327.
19. Wainberg MA, Friedland G: Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998, 279:1977-1983.
20. Ho D, Neumann A, Perelson A, Chen W, Leonard J, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
21. Wei X, Ghosh S, Taylor M, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
22. Holodniy M, Katzenstein D, Israelski D, Merigan T: Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J Clin Invest 1991, 88:1755-1759.
23. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
24. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency with infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
25. Montaner J, Reiss P, Cooper D, et al.: A randomized, double-blinded trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: The INCAS Trial. JAMA 1998, 279:930-937.
26. Wong J, Hezareh M, Günthard H, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
27. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active retroviral therapy. Science 1997, 278:1295-1300.
28. Gupta P, Mellors J, Kingsley L, et al.: High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol 1997, 71:6271-6275.
29. Vernazza PL, Gilliam BL, Flepp M, et al.: Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997, 11:1249-1254.
30. Cohen M, Hoffman I, Royce R, et al.: Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 1997, 349:1868-1873.
31. Yerly S, Rakik A, Kinloch-de-Loes S, et al.: Prévalence de la transmission de virus résistant à la zidovudine en Suisse. Schwiez Med Wochenschr 1996, 126:1845-1848.
32. D'Aquila RT, Johnson VA, Welles SL, et al.: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995, 122:401-408.
33. 3: a double-blind, randomized, controlled trial. Ann Intern Med 1995, 123:561-571.
34. Goudsmit J, de Ronde A, Ho D, et al.: Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine-resistance mutation at codon 215 of reverse transcriptase. J Virol 1996, 70:5662-5664.
35. Larder B, Kemp S, Harrigan P: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
36. Back N, Nijhuis M, Keulen W, et al.: Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996, 15:4040-4049.
37. Davies J: The Myth of Addiction. Reading: Harwood; 1994.